SPRY: Multiplikator P/S ARS Pharma
ARS Pharmaceuticals generates revenue through the sale of innovative emergency care products, offering a needle-free nasal spray for allergy relief. The GURU.Markets terminal displays a chart of the company's market cap-to-revenue ratio, where the 3.10 metric serves as the target level. Revenues are based on sales of the drug neffy, creating a unique therapy ecosystem that attracts patients who fear injections, despite FDA regulatory risks.
Rincian metrik lan analitis perusahaan ARS Pharma (SPRY)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Rasio Kabeh Utang marang Dana Pribadi ARS Pharmaceuticals|SPRY - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang ekuitas ARS Corp|SPRY - Gunggung utang perusahaan|Rasio utang marang aset resik ARS Pharma|SPRY - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan ARS Pharmaceuticals|Rasio jangkoan perantara ars-pharma.com
- informasi bathi lan kelipatan valuasi:
SPRY - Bathi resik perusahaan|Bathi mangsa ngarep ARS Pharmaceuticals|SPRY - Pangali P/E|Pangali Forward P/E ARS Pharmaceuticals Inc|SPRY - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan ARS Pharma|SPRY - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan ARS Pharmaceuticals|SPRY - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan ars-pharma.com|SPRY - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep ARS Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:ars-pharma.com, SPRY
Future revenues for ARS Pharmaceuticals (SPRY) depend on the commercial success of the neffy nasal spray, making a market valuation analysis based on revenue critically important. The price/sales ratio reflects the relationship between market capitalization and actual sales, allowing investors to assess the extent to which market expectations are inflated relative to the current scale of the business and to determine the risk of a potential asset correction.
Perusahaan pesaing
HLN (haleon.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S KVUE (Kenvue)|Multiplikator P/S Verona Pharma PLC VRNA|MENS - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan LGND (Ligand Corp)|Amneal Pharmaceuticals (AMRX) - Rasio rega marang pendapatan|PRGO - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan ALVO|LQDA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANIP: Rasio rega marang dodolan|Multiplikator P/S MNKD (MannKind Corporation)|Rasio kapitalisasi pasar marang pendapatan AMPH|Pacira BioSciences, Inc. - Multiplikator P/S|TBPH - Multiplikator P/S|Aquestive Pharma (AQST) - Rasio rega marang pendapatan|scPharmaceuticals - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Tectonic Therapeutic Inc.|Kapitalisasi marang pendapatan tonixpharma.com (TNXP)|Multiplikator P/S SXTC|Multiplikator P/S eupraxiapharma.com (EPRX)|Multiplikator P/S BHST (BioHarvest)|EXOZ - Kapitalisasi marang pendapatan|Oramed Pharma - Multiplikator P/S|Rega marang dodolan Entera Bio Ltd.|HYFT (MindWalk Holdings Inc.) - Kapitalisasi marang pendapatan|ABVC BioPharma Inc. (ABVC) - Multiplikator P/S|Kapitalisasi marang pendapatan CPIX|QNTM (Quantum BioPharma Corp) - Kapitalisasi marang volume dodolan|Multiplikator P/S FGEN|Koefisien rega marang pendapatan telomirpharma.com|Multiplikator P/S RANI (Rani Therapeutics Holdings, Inc.)|SNYR - Kapitalisasi marang pendapatan|Rallybio Corp. - Multiplikator P/S|LEXX - Multiplikator P/S|Pulmatrix, Inc. (PULM) - Rasio rega marang pendapatan|PTHL (Pheton Holdings) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Aptorum Group Ltd|Lyra Therapeutics Inc. (LYRA) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Impact BioMedical (IBO)|Koefisien rega marang pendapatan tnfpharma.com|Rasio rega marang pendapatan cbdMD YCBD|PRFX (painreform.com) - Rasio rega marang dodolan|CYTO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan LIPO (Lipella Pharmaceuticals Inc)|OPTN (Optinose) - Kapitalisasi marang pendapatan|Rega marang dodolan Pieris Pharma (PIRS)|Rasio rega marang pendapatan Procaps Group S.A.|petrospharma.com - Rasio rega marang dodolan|Multiplikator P/S QLI|SLRN (Acelyrin Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S TFFP (TFF Pharma)
